Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

3.65 EUR

0.00 %

5,585 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

0.00 %
-11.41 %
-1.88 %
-4.20 %
-21.67 %
-19.07 %
-12.78 %
-44.53 %
-20.31 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
78.3M EUR
Turnover
330.71K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Buy
Target price
Updated
17.12.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.2.
2026

Annual report '25

6.5.
2026

Interim report Q1'26

8.5.
2026

General meeting '26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Juha has made a new report on Optomed, in which the share issue and its effects have now been updated: Inderes Optomed: Anti takana ja kasvua edessä - Inderes Optomedin suunnattu osakeanti tehtiin mielestämme alle käyvän arvon, mutta kerätty 6 MEUR tarvittiin erityisesti Lumon FDA...
22 hours ago
by Jussi
29
Optomed has stated that it will conduct extensive clinical trials with Lumo in cooperation with an AI partner. At the same time, this will also secure 510k for Lumo, as there is now PJZ. One would think that the start of these trials would be announced. I would assume they will start...
8 hours ago
by Juha Kinnunen
26
Now it will be interesting to see if Optomed publishes a press release about this. In my opinion, this is rather positive news, which reduces uncertainty regarding the China cooperation arrangement. Now they cannot even invoke confidentiality clauses.
yesterday
by Bob Fleming
23
A pilot in seven localities is starting in India. I wonder if a few Optomed cameras have also found their way into the pilot phase? gktoday.in India Launches AI-Based Diabetic Retinopathy Screening Programme – GKToday India has launched its first Artificial Intelligence driven community...
23 hours ago
by Artoh1
15
From Optomed’s perspective, the FDA’s new RWE guideline is clearly positive, as it enables the utilization of real-world data supporting Lumo’s approval without heavy individual-level patient data. In practice, this can speed up Lumo’s FDA process, especially if the application or...
yesterday
by Mr. Stock
14
In 2026, AI will normalize and become established in clinical routine The value of companies like Optomed will no longer be based on hype or technological appeal, but on real evidence and adoption. Success requires that products like Lumo and Aurora AEYE integrate into electronic...
11 hours ago
by Mr. Stock
9
@Juha_Kinnunen : ““““““““ In our forecasts, we assume that Lumoa with AI will not be significantly sold in the United States before 2028. Therefore, in the coming years, growth will primarily depend on Aurora AEYE, according to our assessment. ““““““““ How did you come to that conclusion...
12 hours ago
by j.sälli
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.